AstraZeneca

News

AZ pays $775m to settle patent dispute with Chugai over Ulto...

AstraZeneca has resolved a lingering liability following its takeover of Alexion with an agreement to pay $775 million to settle a patent dispute with Chugai Pharma, Roche's Japanese subsid

News

Update: FDA clears first generic of AZ's blockbuster Symbico...

Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca's top-selling respiratory drug Symbicort, although launch plans remain

News

Merck trial of Keytruda, Lynparza combo in prostate cancer f...

Merck & Co's two powerhouse oncology drugs – Keytruda and Lynparza – have failed to show efficacy when used in combination for patients with previously treated metastatic castration-res

News

FDA says no to AZ's Fasenra for nasal polyp indication

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketi

News

AZ, Merck get FDA okay for Lynparza as adjuvant breast cance...

The FDA has cleared AstraZeneca and Merck & Co's Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending its lead over pretenders to its PARP inhibitor crown.

News

Jardiance pulls ahead of Forxiga with heart failure approval...

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has become the first drug in the class to be approved in the EU for all adults with symptomatic chronic heart failure (CHF), g

AZ pays $775m to settle patent dispute with Chugai over Ulto...

Update: FDA clears first generic of AZ's blockbuster Symbico...

Merck trial of Keytruda, Lynparza combo in prostate cancer f...

FDA says no to AZ's Fasenra for nasal polyp indication

AZ, Merck get FDA okay for Lynparza as adjuvant breast cance...

Jardiance pulls ahead of Forxiga with heart failure approval...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

AstraZeneca

Editor's Picks